An update on the pharmacological treatment of obesity

Current Medical Research and Opinion

Volumn 22, Issue 8, 2006, Pages 1463-1474

  Schnee, David M ^a   Zaiken, Kathy ^a   McCloskey, William W ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Anti obesity agents; Cost; Obesity; Orlistat; Overweight; Sibutramine

Indexed keywords

ALPHA TOCOPHEROL; AMFEBUTAMONE; AMFEPRAMONE; AMPHETAMINE; ANTIHYPERTENSIVE AGENT; CYCLOSPORIN; DECONGESTIVE AGENT; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; LEPTIN; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OPIATE; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; PLACEBO; PSEUDOEPHEDRINE; RETINOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; VITAMIN D; VITAMIN K GROUP; WARFARIN;

CHOLESTASIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEFECATION DISORDER; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; FECES INCONTINENCE; FLATULENCE; HEADACHE; HEALTH CARE PERSONNEL; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; MALABSORPTION; MEDICAL PRACTICE; META ANALYSIS; NERVOUSNESS; OBESITY; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; RESTLESSNESS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; VALVULAR HEART DISEASE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; HUMANS; OBESITY; PHARMACISTS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC;

EID: 33748053939     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X115496     Document Type: Review

References (82)

1. National Institutes of Health, National Heart Lung and Blood Institute, and North American Association for the Study of Obesity. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethseda, MD: National Institutes of Health, 2000
2. U.S. Department of Health and Human Services Center for Disease Control and Prevention National Center for Health Statistics. The National Health and Nutrition Examination Survey (NHANES), 1999-2002
3. Prevalence of overweight and obesity among adults: United States, 1999-2002. Hyattsville, Md: National Center for Health Statistics, Health E-Stats, 2002. Available from http://www. cdc.gov/nchs/products/pubs/pubd/ hestats/obese/obse99.htm [Last accessed 8 January 2005]
4. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US Adults, 1999-2000. JAMA 2002;288:1723-7
5. Prevalence of overweight among children and adolescents: United States, 1999-2002. Hyattsville, Md: National Center for Health Statistics, Health E-stats, 2002. Available from http://www.cdc.gov/nchs/products/pubs/pubd/ hestats/overwght99. htm [Last accessed 8 January 2005]
6. Ogden CL, Flegal KM, Carroll MD, et al. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002;288:1728-32
7. Shepherd TM. Effective management of obesity. J Fam Pract 2003;52:34-42
8. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999;341:1097-105
9. Manson JE, Bassuk SS. Obesity in the United States: a fresh look at its high toll. JAMA 2003;289:229-30
10. Mcginnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993;270:2207-12
11. Overweight and obesity economic consequences: United States, National Center for Chronic Disease Prevention and Health Promotion, 2004. Available from http://www.cdc. gov/nccdphp/dnpa/obesity/economic_consequences.htm [Last accessed 8 January 2005]
12. Krempf M, Louvet JP, Allanic H, et al. Weight reduction and long-term maintenance after 18 month treatment with orlistat for obesity. Int J Obes Relat Metab Disord 2003;27:591-7
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
14. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003;289:2560-72
15. Campbell ML, Mathys ML. Pharmacologic options for the treatment of obesity. Am J Health Syst Pharm 2001;58:1301-8
16. Greenberg I, Chan S, Blackburn G. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry 1999;60(Suppl 21):31-6
17. Hill JO, Hauptman J, Anderson J, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999;69:1108-16
18. Arerburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Int Med 2004;164:994-1003
19. Finer N. Pharmacotherapy of obesity. Best Pract Res Clin Endocrinol Metab 2002;16:717-42
20. Wadden TA, Berkowitz RI, Womble L, et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000;8:431-7
21. Weigle DS. pharmacological therapy of obesity: past, present, and future. J Clin Endocrinol Metab 2003;88:2462-9
22. Kolanowski J. a risk-benefit assessment of anti-obesity drugs. Drug Safety 1999;2:119-31
23. Weintraub M, Hasday JD, Mushlin AI, et al. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984;144:1143-8
24. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002;346:591-602
25. Product information on Ionamin. Celltech Pharmaceuticals, Rochester, NY, USA, 2001
26. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343:1826-32
27. Product Information on Meridia. Abbott Laboratories, North Chicago IL, USA, 2004
28. Product Information on Xenical. Roche Laboratories, Nutley NJ, USA, 2005
29. Fleming T, editor. Redbook pharmacy's fundamental resource. 2005 ed. Montvale, NJ: Thomson PDR, 2005
30. Thearle M, Aronne LJ. Obesity and pharmacologie therapy. Endocrinol Metab Clin North Am 2003;32:1005-24
31. Carek PJ, Dickerson LM. Current concepts in the pharmacological management of obesity. Drugs 1999;57:883-904
32. Munro JF, MacCuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968;1:352-4
33. Jick H, Vasilaskis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:713-8
34. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999;33:968-78
35. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes 2002;26(Suppl 4):S29-33
36. Ryan DH. Use of Sibutramine to treat obesity. Prim Care 2003;30:405-26
37. Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999;7:363-9
38. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003;26:1027-48
39. Wadden TA, Berkowitz RI, Sarwer DB, et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med 2001;161:218-27
40. McMahon FG, Fujioka K, Singh BN. Efficacy and safety of sibutramine in obese white and African American patients with hypertension. Arch Intern Med 2000;160:2185-91
41. Wirth A, Krause J. Long-term weight loss with sibutramine a randomized controlled trial. JAMA 2001;286:1331-9
42. Dujovne CA, Zavoral JH, Rowe E, et al. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001;142:489-97
43. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-98
44. James WP, Astrup A, Finer N, et al. for the STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000;356:2119-25
45. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000;94:152-8
46. Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very-low calorie diet: a randomization blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-84
47. Weintraub M, Rubio A, Golik A, et al. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 1991;50:330-7
48. Hanotin C, Thomas F, Jones SP, et al. Efficiency and tolerability of sibutramine in obese patients: a dose ranging study. Int J Obes Relat Metab Disord 1998;22:32-8
49. Jones SP, Smith IG, Kelly F. Long-term weight loss with sibutramine. Int J Obes 1995;19(Suppl 2):41
50. Leung WY, Thomas GN, Chan JC, et al. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003;58-80
51. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor ior the management of obesity. Pharmacotherapy 2000;20:270-9
52. Lucas KH, Kaplan-Machlis B. Orlistat - a novel weight loss therapy. Ann Pharmacother 2001;35:314-28
53. Ballinger A, Peikin SR. Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol 2002;440:109-17
54. Hollander P. Orlistat in the treatment of obesity. Prim Care 2003;30:427-40
55. Davidson MH, Hauptman J, Digrolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial. JAMA 1999;281:235-42
56. Sjostrom L, Rissanen A, Andersen T, et al. Randomized placebo-controlled trial of orlistat tor weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-72
57. Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentrc study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metah Disord 1999:306-13
58. Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000;8:49-60
59. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998;54:125-32
60. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (RO-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995;19:221-6
61. Kelly DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated Type 2 diabetes. Diabetes Care 2002;25:1033-41
62. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with Type 2 diabetes treated with metformin. Diabetes Care 2002;25:1123-8
63. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to Type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-6
64. Tiikkaninen M, Bergholn R, Rissanen A, et al. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr 2004;79:22-30
65. Hvizdos KM, Markham A. Orlistat a review of its use in the management of obesity. Drugs 1999;58:743-60
66. Malone DC, Raebel MA, Porter JA, et al. Cost-effectiveness of sibutramine in the LOSE weight study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. J Manag Care Pharm 2005;11:458-68
67. Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making 2004;24:9-19
68. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;505-12
69. Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002;25:303-8
70. Goldstein DJ, Rampey AH, Roback PJ, et al. Efficacy and safety of long-term fluoxetine treatment of obesity-maximizing success. Obes Res 1995;3(Suppl 4):481S-90
71. Wadden TA, Bartlett SJ, Foster GD, et al. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res 1995;3:549-57
72. Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001;161:1814-24
73. Anderson JW, Greenway EL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633-41
74. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11:722-33
75. Korner J, Aronne LJ. Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab 2004;89:2616-21
76. Lee DW, Leinung MC, Rozhavskaya-Arena M, et al. Leptin and the treatment of obesity: its current status. Eur J Pharmacol 2002;440:129-39
77. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999;282:1568-75
78. Zhaoping L, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46
79. Sari BR, Balci MK, Cakir M, et al. Comparison of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004;30:159-67
80. Dastani HB, Brown CM, O'Donnell DC. Combating the obesity epidemic: community pharmacists' counseling on obesity management. Ann Pharmacother 2004;38:1800-4
81. Healthy People 2010. Available from http://www.healthypeople. gov/document/html/objectives/19-02.htm [Last accessed 24 October 2005]
82. American Diabetes Association. All about diabetes. Available from http://www.diabetes.org/home.jsp [Last accessed 24 October 2005]